Events2Join

Updates on Liquid Biopsy for Advanced NSCLC


Circulating tumor DNA to guide diagnosis and treatment of localized ...

∙ Scagliotti, G.V. ... Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J Thorac ...

Liquid Biopsy in EGFR+ NSCLC - CCO

If you obtain a suitable tissue biopsy, you can certainly still test tissue first and use liquid biopsy as needed. However, data from recent prospective studies ...

Detecting an ALK Rearrangement, Treating Patients with Cell Lung ...

Recent advances in liquid biopsy methodologies now make it possible to molecularly characterize tumors from a peripheral blood draw to gain ...

Liquid biopsy-based decision support algorithms for diagnosis and ...

Protein TMs and ctDNA measured in liquid biopsy could support diagnosis and subtyping of lung cancer. •. Liquid biopsy decision-support ...

Case report: Liquid biopsy, the sooner the better? - Frontiers

The detection of circulating tumor DNA (ctDNA) by liquid biopsy is taking an increasing role in thoracic oncology management due to its predictive and ...

Brief Report: Discordance Between Liquid and Tissue Biopsy-Based ...

Liquid biopsy and next-generation sequencing of circulating tumor DNA is increasingly used at the time of diagnosis of non-small cell lung ...

Liquid Biopsy

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for ... Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the ...

The Expanding Potential of Liquid Biopsy to Detect and Monitor ...

Liquid biopsies are increasingly used to detect and monitor cancer. Research on liquid biopsies was featured at the AACR Annual Meeting ...

Liquid Biopsy: The Key Weapon for Real-Time Monitoring of ...

Monitoring the response to ICI administration in patients with advanced-stage NSCLC is another field of interest for liquid biopsy.

Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell ...

We describe the main blood biomarkers evaluated in patients with metastatic nonsmall cell lung cancer before/during immune checkpoint inhibitor treatment, with ...

It's Time to Use Liquid Biopsies for Newly Diagnosed NSCLC

A liquid biopsy identifies biomarkers in patients with NSCLC at a higher rate compared with tissue genotyping and with a faster turnaround ...

Mutated circulating tumor DNA as a liquid biopsy in lung cancer ...

Liquid biopsy can greatly contribute to better detection and management of lung cancer. ctDNA detection in liquid biopsies is a powerful ...

Liquid Biopsy for Lung Cancer: 5 Facts To Know

3. Liquid Biopsies Can Improve Lung Cancer Treatment ... The DNA inside a tumor can change over time, leading to different genomic profiles within ...

Liquid Biopsy Accurately Detects Mutations in Advanced NSCLC

Droplet digital polymerase chain reaction (ddPCR)-based plasma genotyping-referred to as liquid biopsy-exhibited perfect specificity in ...

Liquid Biopsy: Past, Present, Future | American Cancer Society

“Another way researchers have used ctDNA is to monitor an advanced cancer for genetic changes that might influence treatment,” Lichtenfeld says.

Liquid Biopsy: What It Is & Procedure Details - Cleveland Clinic

A liquid biopsy is a blood test that detects signs of cancerous tumors, including tumor cells and cancer cell DNA.

Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB ...

Most evidence in favor of using ctDNA changes as a surrogate for therapeutic response or progression comes from studies with a focus on advanced ...

Case for Liquid Biopsies Builds in Advanced Lung Cancer

For patients with advanced lung cancer, a non-invasive liquid biopsy may be a more effective and suitable alternative to the gold standard ...

Lung Cancer Study Published in JAMA Oncology Shows ...

... liquid biopsy blood test to guide treatment of patients with advanced NSCLC. An accompanying editorial, authored by oncologists from Harvard ...

Liquid Biopsy Advances in Lung Cancer and Glioblastoma Research

In non-small cell lung cancer (NSCLC), detecting actionable mutations through ctDNA profiling can guide the investigation of targeted therapy.